Denali Therapeutics Inc. (DNLI, Financial) is a biotechnology company developing drugs totreat neurological disorders. Shares fell after an interim update reporting mixed results from its Phase 1/2 study of a program in treating Hunter syndrome. We remain optimistic that Denali will be successful with its suite of approaches targeting the brain.
From Ron Baron (Trades, Portfolio)'s Baron Growth Fund third-quarter 2021 letter.